Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Sold by American Century Companies Inc.

American Century Companies Inc. lowered its position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 3.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,096,704 shares of the company’s stock after selling 34,004 shares during the period. American Century Companies Inc. owned 0.82% of Centessa Pharmaceuticals worth $26,595,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of Centessa Pharmaceuticals by 4.8% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock valued at $252,000 after acquiring an additional 870 shares during the last quarter. HighVista Strategies LLC boosted its holdings in Centessa Pharmaceuticals by 4.3% in the second quarter. HighVista Strategies LLC now owns 40,684 shares of the company’s stock valued at $535,000 after purchasing an additional 1,664 shares in the last quarter. DNB Asset Management AS purchased a new position in Centessa Pharmaceuticals in the third quarter valued at approximately $218,000. Campbell & CO Investment Adviser LLC raised its holdings in Centessa Pharmaceuticals by 55.5% during the third quarter. Campbell & CO Investment Adviser LLC now owns 25,845 shares of the company’s stock worth $627,000 after purchasing an additional 9,226 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Centessa Pharmaceuticals by 4.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 317,574 shares of the company’s stock worth $4,173,000 after buying an additional 14,928 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Iqbal J. Hussain sold 38,951 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total transaction of $979,617.65. Following the transaction, the insider directly owned 57,645 shares of the company’s stock, valued at approximately $1,449,771.75. This trade represents a 40.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 7.09% of the stock is currently owned by corporate insiders.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA opened at $25.95 on Monday. The company’s 50 day simple moving average is $24.45 and its 200-day simple moving average is $23.99. The firm has a market cap of $3.79 billion, a PE ratio of -14.18 and a beta of 1.54. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $9.60 and a 12-month high of $30.58. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on CNTA shares. Wells Fargo & Company increased their target price on shares of Centessa Pharmaceuticals from $30.00 to $35.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Chardan Capital reissued a “buy” rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, January 2nd. Guggenheim upped their price objective on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. Finally, Wolfe Research started coverage on Centessa Pharmaceuticals in a research report on Tuesday, February 24th. They set an “outperform” rating and a $40.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $39.80.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.